UBS has given Merck KGaA a 'Buy' rating and set a target price of 190 euros after the company's recent capital market day. Analyst Matthew Weston is confident in the stock's attractive valuation and supports the positive outlook for the pharmaceutical and specialty chemicals group.

Merck KGaA is a global leader in pharmaceuticals and chemicals, generating revenue from various product families. These include scientific and biotechnological research solutions (44.2%), pharmaceutical products (38.4%), and performance materials for the electronics industry (17.4%). The company's sales are geographically diversified, with significant contributions from the USA (26.8%), Europe (24%), and China (12.9%).

Analyst estimates show a consensus recommendation of 'Buy' for Merck KGaA, with an average target price of 186.59 euros. This indicates a potential upside of 15.25% from the last closing price of 161.90 euros.